Form 4: Teva Pharmaceutical Executive Conway Sells Shares to Cover Tax Obligations

Vikki L. Conway, Acting Head of Global Human Resources at Teva Pharmaceutical Industries, sold 1,366 ordinary shares on February 28, 2024, to cover tax withholding obligations related to vesting restricted share units.

Summary

• Vikki L. Conway, an officer at Teva Pharmaceutical Industries, reported a transaction on February 28, 2024, involving ordinary shares.
• Conway acquired 4,294 shares through the vesting of restricted share units and simultaneously sold 1,366 shares to cover tax obligations.
• The sale was executed at a weighted average price of $13.116 per share, with individual transactions ranging from $13.01 to $13.19.
• Following the transaction, Conway directly owns 2,928 ordinary shares.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2023.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, suggesting it was planned and not based on immediate market sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading by corporate insiders. This filing indicates routine transactions related to executive compensation and tax obligations.

Comparison to Industry Standards

• Executive compensation packages often include restricted share units that vest over time.
• Selling shares to cover tax obligations upon vesting is a common practice among executives.
• Rule 10b5-1 trading plans are frequently used by corporate insiders to schedule transactions and avoid accusations of insider trading.

Key Dates